Astra's Foscavir (foscarnet)
Executive Summary
The NDA for foscarnet in treating cytomegalovirus retinitis in AIDS patients is slated for review by FDA's Antiviral Drugs Advisory Committee at its June 12 meeting scheduled at the Sheraton-Potomac in Rockville, Maryland. The NDA was filed in September 1990. In mid-April, ACT UP called for approval of the drug within 60 days.